New Antibody-Drug conjugate targets Hard-to-Treat cancers

NCT ID NCT06224855

Recruiting now Disease control Sponsor: Hangzhou DAC Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety, find the right dose, and get an early look at whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DXC006 (an antibody-drug conjugate)
What this could lead to: If safe and effective, DXC006 could offer a new treatment option for people with advanced solid tumors or blood cancers who have run out of standard therapies.
What could go wrong: This is an early, first-in-human trial, so the drug may not work or could cause serious side effects. The results are preliminary and may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neoplasm neuroblastoma plasma cell myeloma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Anhui Cancer Hospital
RECRUITING

Hefei, Anhui, 230031, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.